

Jeffrey I Zwicker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/387969/publications.pdf>

Version: 2024-02-01

97
papers

5,811
citations

117625

34
h-index

76900

74
g-index

97
all docs

97
docs citations

97
times ranked

7284
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	27.0	1,237
2	Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. <i>Blood</i> , 2020, 136, 2881-2892.	1.4	479
3	Tumor-Derived Tissue Factor-Bearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy. <i>Clinical Cancer Research</i> , 2009, 15, 6830-6840.	7.0	441
4	Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2133-2137.	3.8	232
5	Postdischarge thrombosis and hemorrhage in patients with COVID-19. <i>Blood</i> , 2020, 136, 1342-1346.	1.4	194
6	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	3.4	154
7	Lenalidomide enhances anti-myeloma cellular immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 39-49.	4.2	149
8	Cancer-associated thrombosis. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 126-136.	4.4	146
9	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171.	12.4	140
10	Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1246-1249.	3.8	140
11	Tissue Factor-Bearing Microparticles and Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 728-733.	2.4	132
12	Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, 82-86.e1.	1.5	132
13	Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. <i>Blood</i> , 2015, 126, 494-499.	1.4	128
14	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec) Tj ETQq0 0 2gBT /Overclock 10 Tf		
15	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	110
16	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	3.8	107
17	Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. <i>JCI Insight</i> , 2017, 2, e89373.	5.0	96
18	Aggressive cutaneous T-cell lymphomas after TNF-blockade. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 660-662.	1.2	93

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1736-1740.	3.8	93
20	Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 72-76.	3.8	85
21	Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. <i>Blood</i> , 2017, 129, 3379-3385.	1.4	77
22	Therapeutic Implications of Protein Disulfide Isomerase Inhibition in Thrombotic Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 16-23.	2.4	73
23	Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 796-800.	3.8	72
24	Tissue Factor-Bearing Microparticles and Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 195-198.	2.7	66
25	Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. <i>Thrombosis Research</i> , 2012, 130, 361-368.	1.7	61
26	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1928-1931.	3.8	55
27	The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. <i>Blood</i> , 2006, 108, 1280-1283.	1.4	52
28	Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. <i>Thrombosis Research</i> , 2010, 125, S89-S91.	1.7	52
29	Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 076-085.	3.4	52
30	Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2349-2357.	3.8	50
31	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	2.3	47
32	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1792-1796.	1.6	45
33	Heparin induced thrombocytopenia antibodies in Covid-19. <i>American Journal of Hematology</i> , 2020, 95, E295.	4.1	45
34	Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2599-2601.	3.8	38
35	Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021, 26, e2-e7.	3.7	33
36	Intracranial hemorrhage in cancer patients treated with anticoagulation. <i>Thrombosis Research</i> , 2016, 140, S60-S65.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Adjuvant low-dose rituximab and plasma exchange for acquired TTP. <i>Blood</i> , 2019, 134, 1106-1109.	1.4	30
38	Impedance-Based Flow Cytometry for the Measurement of Microparticles. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 819-823.	2.7	28
39	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.	5.2	28
40	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	3.8	26
41	Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1449-1451.	3.8	24
42	Revisiting the mechanistic basis of the French Paradox: Red wine inhibits the activity of protein disulfide isomerase in vitro. <i>Thrombosis Research</i> , 2016, 137, 169-173.	1.7	23
43	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies: TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	3.8	23
44	Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. <i>Blood Advances</i> , 2021, 5, 5546-5553.	5.2	23
45	The intersection of protein disulfide isomerase and cancer associated thrombosis. <i>Thrombosis Research</i> , 2018, 164, S130-S135.	1.7	22
46	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	3.8	22
47	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260.	5.2	22
48	Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. <i>Blood Advances</i> , 2021, 5, 4521-4534.	5.2	19
49	Measurement of Platelet Microparticles. <i>Methods in Molecular Biology</i> , 2012, 788, 127-139.	0.9	17
50	Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 55-59.	1.0	16
51	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020, 98, 106459.	0.8	16
52	Differences Between Students in Problem-Based and Lecture-Based Curricula Measured by Clerkship Performance Ratings at the Beginning of the Third Year. <i>Teaching and Learning in Medicine</i> , 2002, 14, 211-217.	2.1	14
53	Accounting for death as a competing risk in cancer-associated thrombosis studies. <i>Thrombosis Research</i> , 2012, 129, S85-S87.	1.7	14
54	Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 489-501.	3.8	14

#	ARTICLE	IF	CITATIONS
55	Transfusion-associated <i>Naiplasma phagocytophilum</i> infection in a pregnant patient with thalassemia trait: a case report. <i>Transfusion</i> , 2015, 55, 719-725.	1.6	13
56	Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 860-865.	2.3	13
57	How Long Is Long Enough? Extended Anticoagulation for the Treatment of Cancer-Associated Deep Vein Thrombosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3596-3599.	1.6	11
58	Risking thromboembolism: podoplanin and glioma. <i>Blood</i> , 2017, 129, 1742-1743.	1.4	11
59	Anticoagulation in the Setting of Primary and Metastatic Brain Tumors. <i>Cancer Treatment and Research</i> , 2019, 179, 179-189.	0.5	10
60	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	3.8	10
61	Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. <i>Blood Advances</i> , 2021, 5, 2055-2062.	5.2	8
62	Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. <i>Haematologica</i> , 2022, 107, 1106-1110.	3.5	8
63	Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2825-2834.	3.8	8
64	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant. <i>Acta Haematologica</i> , 2015, 133, 347-353.	1.4	7
65	Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in <i>JAK2</i> -Mutated Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2021, 27, 5708-5717.	7.0	7
66	Trousseau's Syndrome Revisited: Tissue Factor-Bearing Microparticles in Pancreatic Cancer. <i>Blood</i> , 2005, 106, 259-259.	1.4	7
67	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. <i>Blood</i> , 2013, 122, 3928-3928.	1.4	7
68	Unconventional approaches to the prevention of cancer associated thrombosis. <i>Thrombosis Research</i> , 2014, 133, S44-S48.	1.7	5
69	Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL). <i>Blood</i> , 2019, 134, 168-168.	1.4	5
70	A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2082-2082.	3.8	4
71	Postpartum haemorrhage in women with mild factor XI deficiency. <i>Haemophilia</i> , 2020, 26, 663-666.	2.1	4
72	Challenges in anticoagulation for patients with brain tumors. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101350.	1.7	4

#	ARTICLE	IF	CITATIONS
73	A microcomputer program for calculating cell population doubling time in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 37, 203-210.	2.3	3
74	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , 2012, 142, 265-266.	0.8	3
75	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 325-326.	3.8	3
76	Inpatient prophylaxis in cancer patients: where is the evidence?. <i>Thrombosis Research</i> , 2020, 191, S85-S90.	1.7	3
77	Efficacy of Adjuvant Low Dose Rituximab and Plasma Exchange for Acquired TTP with Severe ADAMTS13 Deficiency – Results of the ART Study. <i>Blood</i> , 2018, 132, 374-374.	1.4	3
78	Eculizumab Therapy Results in Rapid and Sustained Decreases in Markers of Thrombin Generation and Inflammation in Patients with PNH. <i>Blood</i> , 2008, 112, 407-407.	1.4	3
79	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. <i>Blood</i> , 2011, 118, 948-948.	1.4	3
80	Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. <i>Blood Advances</i> , 2022, 6, 1559-1565.	5.2	3
81	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-SSC subcommittee on hemostasis and malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1920-1927.	3.8	3
82	Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004012.	8.4	3
83	Pulmonary Zygomycosis in a Non-neutropenic Patient With Myelodysplastic Syndrome on Lenalidomide. <i>Respiratory Care</i> , 2012, 57, 1175-1177.	1.6	2
84	The impact of warfarin on overall survival in cancer patients. <i>Thrombosis Research</i> , 2022, 213, S113-S119.	1.7	2
85	Rosuvastatin Lowers Circulating Tissue Factor Antigen-Bearing Microparticles In Metastatic Breast Cancer: A Phase II, Multi-Dose, Randomized Trial (MicroSTAT Trial). <i>Blood</i> , 2013, 122, 579-579.	1.4	1
86	Animal Models of Arterial and Venous Thrombosis. <i>Blood</i> , 2014, 124, SCI-2-SCI-2.	1.4	1
87	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e35.	1.5	0
88	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e13.	1.5	0
89	Scattering the spotlight on microparticles. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 185-186.	3.8	0
90	Timing and Safety of Postpartum Enoxparin.. <i>Blood</i> , 2006, 108, 4110-4110.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	1.4	0
92	Progestin-Only Contraceptives and the Risk of Venous Thromboembolism: Systematic Review and Meta-Analysis.. Blood, 2011, 118, 3344-3344.	1.4	0
93	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066.	1.4	0
94	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. Blood, 2013, 122, 127-127.	1.4	0
95	Risk of Intracranial Hemorrhage Associated with Enoxaparin Administration in Patients with Brain Metastasis. Blood, 2014, 124, 348-348.	1.4	0
96	Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes. , 2016, , 503-517.		0
97	Thrombophilia and Thrombocytopenia in the Pregnant Woman. , 2017, , 55-76.		0